.jpeg)
{{ variable.name }}
Acalabrutinib has emerged in the field of hematological cancer treatment with its excellent clinical performance and unique therapeutic mechanism since its inception.
1. Common name: Acalabrutinib
2. Trade name: Calquence® (original drug)
3. Dosage form: Capsule
Acalabrutinib is a Bruton tyrosine kinase (BTK) ) inhibitor, suitable for the treatment of a variety of B-cell hematological malignancies, such as:
1., Mantle cell lymphoma (MCL)
2., Chronic lymphocytic leukemia (C LL)
3. Small lymphocytic lymphoma (SLL)
1. Specifications:100mg.
2. Characteristics: 100mg capsule.
Active ingredient: Acalatinib.
The recommended dose is usually 100 mg orally every 12 hours¹ until disease progression or unacceptable toxicity occurs. Swallow the tablets whole with water, with or without food.
For patients who experience specific adverse reactions (such as infection, bleeding, cytopenia, arrhythmia), treatment needs to be interrupted, the dose reduced, or the drug permanently discontinued. Specific adjustment plans need to follow clinical guidelines and physician guidance.
1. How to take the medicine: Swallow the capsule whole. Do not open, chew or dissolve the contents of the capsule.
2. Diet: Can be taken with or without food.
3. Missed dose: If you miss a dose, you should take the regular dose at the next scheduled time and no additional dose should be taken.
4. Vomiting: If you vomit after taking the medicine, you should not take additional doses. You should take the regular dose at the next scheduled time.
Pregnant women, lactating women, children, the elderly and patients with liver and kidney dysfunction must be used with special caution and strictly follow medical advice. The doctor will conduct a benefit-risk assessment and may adjust the dose based on the specific situation.
Common adverse reactions include headache, diarrhea, musculoskeletal pain, rash, bleeding, infection (such as respiratory tract infection), decreased blood cell count (such as neutropenia), etc. More serious side effects may also occur, such as serious infections, cardiac arrhythmias, etc.
It is contraindicated in patients with known severe allergic reactions to acalabrutinib or any excipients.
Concurrent use with strong CYP3A inhibitors or inducers may affect the plasma concentration of acalabrutinib. Concurrent use should be avoided or the dosage should be adjusted under the guidance of a doctor. Anticoagulants and antiplatelet drugs may increase the risk of bleeding.
Storage at room temperature between 20°C and 25°C (68°F and 77°F) is generally recommended. Should be kept in original container, protected from moisture.